SEC 1745 POTENTIAL PERSONS WHO ARE TO RESPOND TO THE COLLECTION OF INFORMATION
(6-00) CONTAINED IN THIS FORM ARE NOT REQUIRED TO RESPOND UNLESS THE FORM
DISPLAYS A CURRENTLY VALID OMB CONTROL NUMBER.
-------------------------------------------------------------------------------
--------------------------
OMB APPROVAL
--------------------------
OMB Number: 3235-0145
--------------------------
Expires: October 31, 2002
--------------------------
Estimated average burden
hours per response...14.9
--------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. ___________)*
ORTHOVITA
-------------------------------------------------------------------------------
(Name of Issuer)
COMMON
-------------------------------------------------------------------------------
(Title of Class of Securities)
068750U102
-------------------------------------------------------------------------------
(CUSIP Number)
MARCH 16, 2001
-------------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
/X/ Rule 13d-1(b)
/ / Rule 13d-1(c)
/ / Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section
of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).
CUSIP No. 068750U102
-------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).
Hambrecht & Quist Capital Management
94-3021090
-------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) / /
(b) /X/
-------------------------------------------------------------------------------
3 SEC USE ONLY
-------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
California
-------------------------------------------------------------------------------
5 SOLE VOTING POWER
NUMBER OF
SHARES
BENEFICIALLY 1,700,000
OWNED BY EACH
REPORTING
PERSON
WITH
-----------------------------------------------------
6 SHARED VOTING POWER
-----------------------------------------------------
7 SOLE DISPOSITIVE POWER
-----------------------------------------------------
8 SHARED DISPOSITIVE POWER
-------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,700,000
-------------------------------------------------------------------------------
10 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES (See Instructions) / /
-------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
10.7%
-------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON (See Instructions)
IA
-------------------------------------------------------------------------------
SCHEDULE 13G EXHIBIT
ITEM 1.
Orthovita
45 Great Valley Parkway
Malvern, PA 19355
ITEM 2.
Hambrecht & Quist Capital Management Incorporated
30 Rowes Wharf - 4th Floor
Boston, MA 02110-3328
(California corporation)
Common stock
CUSIP: 68750U102
ITEM 3.
(e) Investment Adviser
ITEM 4.
Hambrecht & Quist Capital Management Incorporated ("HQCM") disclaims any
beneficial interest in the shares reported in this Schedule 13G.
Moreover, HQCM is of the view that the client accounts that it manages
are not acting as a "group" for purposes of Section 13(d) under the
Securities and Exchange Act of 1934 (the "1934 Act") and that it and
such clients are not otherwise required to attribute to each other the
"beneficial ownership" of securities "beneficially owned" under Rule
13d-3 promulgated under the 1934 Act. Therefore, HQCM is of the view
that the shares held in such accounts should not be aggregated for
purposes of Section 13(d). However, HQCM is making this filing on a
voluntary basis as if all the shares are beneficially owned by HQCM on a
joint basis.
1,700,000 shares of Common stock beneficially owned
10.7% of Common
1,700,000 sole voting power (i) and sole dispositive power (iii)
ITEM 5.
N/A
ITEM 6.
Of the 1,700,000 shares of the Common stock reported above, 1,020,000
shares are held by H&Q Healthcare Investors, a registered investment
company, which represents 6.4% of the issuer's Outstanding Common stock.
ITEM 7.
N/A
ITEM 8.
N/A
E-1
ITEM 9.
N/A
ITEM 10.
By signing below I certify that, to the best of my knowledge and belief,
the securities referred to above were acquired in the ordinary course of
business and were not acquired for the purpose of and do not have the
effect of changing or influencing the control of the issuer of such
securities and were not acquired in connection with or as a participant
in any transaction having such purposes or effect.
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true,
complete and correct.
Date: 4/25/01
----------------------------------------------------------------
Signature:
----------------------------------------------------------------
Name/Title: Kim Carroll, Vice President
Hambrecht & Quist Capital Management Incorporated
E-2